Nuvectis Pharma reports FY2025 net loss $26.4M; cash $31.6M; NXP900 program advancing

Nuvectis Pharma, Inc.

2025-FY EPS reported -$1.32

Net loss $26.4M for FY2025 vs $19.0M in FY2024; includes $6.0M stock-based comp and $2.4M milestone license fees.
Cash and equivalents $31.6M at Dec 31, 2025, up from $18.5M; funded by public offering and ATM facility.
R&D expenses $18.2M (up from $12.9M), G&A $9.4M (up from $6.9M); finance income $1.1M.
NXP900 Phase 1b monotherapy enrolling; combination with osimertinib (EGFR-mutated NSCLC) enrolling; lorlatinib combo pending.
CEO expects current cash to fund operations through multiple Phase 1b milestones into H2 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.